Dyne Therapeutics

Dyne is building a leading muscle disease company focused on advancing innovative life-transforming therapeutics for patients with genetically driven diseases.



Post IPO Equity




Org chart

Joshua Brumm
President & CEO
Wildon Farwell
Chief Medical Officer
Oxana Beskrovnaya
Chief Scientific Officer
Susanna High
Chief Operating Officer
Rick Scalzo
SVP, Head of Finance & Administration
Chris Mix
SVP, Pharmacovigilance
Jonathan McNeill
SVP, Business Development
Francesco Bibbiani
SVP, Head of Development
John Najim
SVP, Chemistry, Manufacturing & Controls
Amy Reilly
SVP, Head of Corporate Communications & Investor Relations
Debra Feldman
VP, Head of Regulatory
Molly White
VP, Global Head of Patient Advocacy & Engagement
Daniel Wilson
VP, Head of Intellectual Property
Kate Mitchell
VP, Head of Human Resources
The Org
helps you hire
great candidates
It takes less than ten minutes to set up your company page.
It’s free to use - try it out today.